Adjuvant Ultra-Hypofractionated vs Hypofractionated Radiotherapy for Early Breast Cancer (UHF vs HF-EBC)
Adjuvant Ultra Hypofractionation Radiotherapy Versus Hypofractionation Radiotherapy in Treatment of Early Invasive Breast Cancer
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Zagazig, Egypt
- Zagazig University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:• Histological diagnosis of breast adenocarcinoma
- Prior breast conservative surgery negative resection margins (3 mm)
- Pathological stage pT1-pT2, N0-1, pT3-N0, M0
- No macroscopic evidence of distant metastases at diagnosis
- Age 18-80 years
- Female patients
- Normal hematological and biochemical laboratory tests
- Written informed consent was obtained from all patients
Exclusion Criteria: • Patients underwent mastectomy.
- Locally advanced disease pT4, N2,3.
- Positive surgical margins
- Prior thoracic radiation
- Synchronous second primary tumor
- Distant metastases
- Pregnancy
- Presence of a concomitant psychiatric disorder precluding an aware informed consent.
- Age >80 years
- Low risk patient meeting all the following criteria (more than or equal 65 years, PT1, grade 1 or 2, +ER, -Her2nu, N0, M0).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Arm A:Adjuvat Ultra-Hypofractionation Radiotherapy
Adjuvant external beam radiotherapy after breast-conserving surgery Total dose: 26 Gy delivered in 5 fractions over 1 week 3D conformal radiotherapy technique without breath-hold Daily fractionation, whole breast irradiation
|
Adjuvant external beam radiotherapy after breast-conserving surgery Total dose: 26 Gy delivered in 5 fractions over 1 week 3D conformal radiotherapy technique without breath-hold Daily fractionation, whole breast irradiation
|
|
Experimental: Arm B: Adjuvant hypofractionation radiotherapy
|
Adjuvant external beam radiotherapy after breast-conserving surgery Total dose: 40 Gy delivered in 15 fractions over 3 week 3D conformal radiotherapy technique without breath-hold Daily fractionation, whole breast irradiation
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Acute Skin Toxicity (CTCAE v5.0)
Time Frame: From start of radiotherapy to 6 weeks post-treatment
|
Incidence and severity of acute skin toxicity (erythema, desquamation, edema) assessed
|
From start of radiotherapy to 6 weeks post-treatment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Late Skin Toxicity and Cosmesis
Time Frame: 12 months post-radiotherapy
|
Incidence of late skin changes (pigmentation, fibrosis) and cosmetic outcomes assessed at 12 months post-radiotherapy using physician assessment and patient-reported outcomes (EORTC QLQ)
|
12 months post-radiotherapy
|
|
Locoregional Recurrence
Time Frame: Up to 24 months post-radiotherapy
|
Rate of locoregional recurrence in the irradiated breast assessed by clinical examination and imaging at follow-up visits
|
Up to 24 months post-radiotherapy
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 11119 (DAIDS ES Registry Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.